New Orphazyme boss will start sales adventure: "It’s all about getting the drug to the market"

The primary objective for Kim Stratton, new CEO of Orphazyme, is to get the company's drug arimocolmal approved and onto the market. To reach this goal, she will use her experience from Shirre and take on a Danish-inspired leadership style.

Kim Stratton, CEO of Orphazyme Photo: Novozymes/ PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles